blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4358991

EP4358991 - COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  13.02.2026
Database last updated on 08.04.2026
FormerRequest for examination was made
Status updated on  29.03.2024
FormerThe international publication has been made
Status updated on  30.12.2022
Most recent event   Tooltip13.02.2026Application deemed to be withdrawnpublished on 18.03.2026  [2026/12]
Applicant(s)For all designated states
Acceleron Pharma, Inc.
126 East Lincoln Avenue
P.O. Box 2000
Rahway, NJ 07065 / US
[2025/15]
Former [2024/18]For all designated states
Acceleron Pharma Inc.
128 Sidney Street
Cambridge, MA 02139 / US
Inventor(s)01 / KUMAR, Ravindra
Cambridge, MA 02139 / US
 [2024/18]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstraße 3
81675 München / DE
[2024/18]
Application number, filing date22829068.017.06.2022
[2024/18]
WO2022US34090
Priority number, dateUS202163213073P21.06.2021         Original published format: US 202163213073 P
[2024/18]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2022271571
Date:29.12.2022
Language:EN
[2022/52]
Type: A1 Application with search report 
No.:EP4358991
Date:01.05.2024
Language:EN
The application published by WIPO in one of the EPO official languages on 29.12.2022 takes the place of the publication of the European patent application.
[2024/18]
Search report(s)International search report - published on:US29.12.2022
(Supplementary) European search report - dispatched on:EP10.04.2025
ClassificationIPC:A61K38/17, A61P9/12, A61P11/00, A61K47/68, C07K14/00, A61K45/06
[2025/20]
CPC:
A61P11/00 (EP); A61K38/179 (US); A61K38/1796 (EP);
A61K45/06 (EP); A61K47/68 (EP); A61P9/12 (EP,US);
C07K14/71 (EP); C12N9/12 (EP); C12Y207/1103 (EP) (-)
Former IPC [2024/18]A61K38/17, A61P9/12, A61P11/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2024/18]
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON PULMONALER HYPERTONIE[2024/18]
English:COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION[2024/18]
French:COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE L'HYPERTENSION PULMONAIRE[2024/18]
Entry into regional phase18.01.2024National basic fee paid 
18.01.2024Search fee paid 
18.01.2024Designation fee(s) paid 
18.01.2024Examination fee paid 
Examination procedure18.01.2024Examination requested  [2024/18]
25.07.2024Amendment by applicant (claims and/or description)
30.10.2025Application deemed to be withdrawn, date of legal effect  [2026/12]
13.11.2025Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2026/12]
Fees paidRenewal fee
31.03.2024Renewal fee patent year 03
10.06.2025Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[E] WO2022192420  (ACCELERON PHARMA INC et al.) [E] 1-20 * see sequences, claims and examples *
 [T] WO2021158695  (ACCELERON PHARMA INC et al.) [T] * see sequences , claims and examples *
 [I] WO2019140283  (KEROS THERAPEUTICS INC et al.) [I] 1-20 * see claims and examples *
 [T]   LIU SHAO-FEI ET AL: "Animal models of pulmonary hypertension due to left heart disease", ANIMAL MODELS AND EXPERIMENTAL MEDICINE, vol. 5, no. 3, 9 February 2022 (2022-02-09), pages 197 - 206, XP093263484, ISSN: 2576-2095, Retrieved from the Internet DOI: 10.1002/ame2.12214 [T] * the whole document *

DOI:   http://dx.doi.org/10.1002/ame2.12214
International search[X] US2021023174  (KUMAR RAVINDRA et al.) [X] 1-5 * entire document *
 [A] WO2021119136  (ACCELERON PHARMA INC et al.) [A] 1-5 * entire document *
 [A] WO2021113544  (ACCELERON PHARMA INC et al.) [A] 1-5 * entire document *
 [A] US2021052698  (SEEHRA JASBIR S et al.) [A] 1-5 * entire document *
 [A] US2019194756  (GRÜNIG EKKEHARD et al.) [A] 1-5 * entire document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.